Drugmaker Sun Pharmaceutical Industries Ltd said that there was a shortage of its generic version of hypertension drug pindolol due to unavailability of supply of the drug’s ingredients. The company said it does not source the active pharmaceutical ingredients (API) of the drug from China, adding that supply of some other APIs was impacted by the coronavirus.
‘We have sufficient inventory of API and raw materials for the short term,’ Sun Pharma said in an email. Last week, the US Food and Drug Administration announced the first coronavirus-related drug shortage in the United States but declined to name the drug in question.
Read EquityPandit’s  Sun Pharma Outlook for the Week